{
  "id": "61f58ef3882a024a1000000b",
  "type": "list",
  "question": "List monoclonal antibodies included in the REGEN-COV.",
  "ideal_answer": "REGEN-COV is a combination of the monoclonal antibodies casirivimab and imdevimab. It has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34716907",
    "http://www.ncbi.nlm.nih.gov/pubmed/34159344",
    "http://www.ncbi.nlm.nih.gov/pubmed/34159343",
    "http://www.ncbi.nlm.nih.gov/pubmed/34587383",
    "http://www.ncbi.nlm.nih.gov/pubmed/34393218",
    "http://www.ncbi.nlm.nih.gov/pubmed/34347950",
    "http://www.ncbi.nlm.nih.gov/pubmed/34673689",
    "http://www.ncbi.nlm.nih.gov/pubmed/34463470"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "REGEN-COV is a cocktail of two human IgG1 monoclonal antibodies (REGN10933 + REGN10987) that targets severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and has shown great promise to reduce the SARS-CoV-2 viral load in COVID-19 patients enrolled in clinical studies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34463470",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Casirivimab and imdevimab (REGEN-COV\u2122) markedly reduces risk of hospitalization or death in high-risk individuals with Covid-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34159344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34347950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the US, the FDA has given Emergency Use Authorization (EUA) for two neutralizing therapeutic monoclonal antibody 'cocktails,' casirivimab and imdevimab (REGEN-COV), bamlanivimab and etesevimab, and one monotherapy, bamlanivimab, for prophylactic post-exposure therapy in individuals at high risk of progressing to severe COVID-19. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34393218",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the US, the FDA has given Emergency Use Authorization (EUA) for two neutralizing therapeutic monoclonal antibody 'cocktails,' casirivimab and imdevimab (REGEN-COV), bamlanivimab and etesevimab, and one monotherapy, bamlanivimab, for prophylactic post-exposure therapy in individuals at high risk of progressing to severe COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34393218",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The emergency use authorization for REGEN-COV (a combination of two monoclonal antibodies, casirivimab and imdevimab) has been revised to include postexposure prophylaxis of COVID-19 in adults and children 12 years of age and older who, if they become COVID-19 positive, are at high risk for severe disease.Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34673689",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34347950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " the FDA has given Emergency Use Authorization (EUA) for two neutralizing therapeutic monoclonal antibody 'cocktails,' casirivimab and imdevimab (REGEN-COV), bamlanivimab and etesevimab, and one monotherapy, bamlanivimab, for prophylactic post-exposure therapy in individuals at high risk of progressing to severe COVID-19. Preclinical and clin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34393218",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34347950",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Casirivimab/imdevimab (Ronapreve\u2122; REGEN-COV\u2122) is a co-packaged combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal antibodies (casirivimab and imdevimab) against the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34716907",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "casirivimab, imdevimab"
}